Reuters logo
BRIEF-Chemocentryx says Avacopan safe and well tolerated at ERA-EDTA congress
June 6, 2017 / 11:56 AM / in 6 months

BRIEF-Chemocentryx says Avacopan safe and well tolerated at ERA-EDTA congress

June 6 (Reuters) - Chemocentryx Inc

* Oral presentations at ERA-EDTA congress highlight fourth potential indication for Avacopan and potential for CCR2 inhibition in focal segmental glomerulosclerosis (FSGS)

* Chemocentryx Inc says Avacopan appeared to be safe and well tolerated Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below